Catheter Precision Announces Strategic Sale of Non-Core Assets to Strengthen Balance Sheet and Accelerate Electrophysiology Growth
Upfront Cash, Equity Participation and Tiered Royalty Structure Providing Long-Term Revenue Upside
FORT MILL, S.C., Feb. 19, 2026 (GLOBE NEWSWIRE) — Catheter Precision, Inc. (NYSE American: VTAK), a leader in advanced electrophysiology solutions, today announced it has entered into a definitive agreement to divest its atherectomy catheter technologies, including associated FDA approvals and patents, to a strategic acquirer.
Following a comprehensive portfolio review, the Company determined that monetizing these non-core assets enhances capital efficiency and sharpens focus on its high-growth electrophysiology platform.
Strategic Rationale
- Focus our capital allocation on core cardiac arrhythmia technologies
- Strengthened balance sheet
- Simplified operating structure with enhanced strategic clarity
Transaction Highlights
- Upfront cash payment following closing of $15,000
- A 5% equity stake in the acquiring company with anti-dilution protection up to $5 million of additional equity capital being invested in the acquiring company
- Ten-year royalty payments agreement on net sales:
- 1.5% baseline
- Increases to 3% on quarterly net sales above $5 million
Value Creation Framework
- Small cash infusion
- Potential long-term equity upside participation
- Recurring revenue potential through performance-based royalties
Management believes the transaction positions the Company to accelerate execution across its electrophysiology product portfolio while maintaining exposure to future commercial success of the divested technologies.
About Catheter Precision
Catheter Precision is a U.S.-based medical device company advancing the treatment of cardiac arrhythmias through differentiated electrophysiology technologies developed in collaboration with leading physicians.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “potential,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “lends,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, the potential long-term equity upside participation in the acquiring company, the potential of recurring revenue through performance-based royalties and our management’s belief that the transaction positions the Company to accelerate execution across its electrophysiology product portfolio while maintaining exposure to future commercial success of the divested technologies. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. Unless otherwise required by law, the Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise and such statements are made only as of the date hereof. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Form 10-K and Form 10-Q’s, including but not limited to the discussion under “Risk Factors” therein, which the Company has filed with the SEC and which may be viewed at www.sec.gov.
CONTACTS:
Investor Relations
973-691-2000
IR@catheterprecision.com
# # #
